2Indexed trials
drug · Product Intelligence
Apixaban
Pipeline Intelligence
Apixaban: 2 indexed trials, 2 sponsors; 6 linked Orange Book patents and 14 FDA-linked events where matched.
2Sponsors
6Orange Book patent links
14FDA-linked events
Development evidence
NCT01924325Xijing Hospital · strokePHASE2, PHASE3
NCT03192215Columbia University · strokePHASE3
FDA / patent evidence
11896586*PEDELIQUIS SPRINKLE · app 2200732041-05-22
11896586ELIQUIS SPRINKLE · app 2200732040-11-22
9326945*PEDELIQUIS · app 2021552031-08-24
9326945ELIQUIS · app 2021552031-02-24
6967208*PEDELIQUIS · app 2021552027-05-21
6967208*PEDELIQUIS SPRINKLE · app 2200732027-05-21
6967208ELIQUIS SPRINKLE · app 2200732026-11-21
6967208ELIQUIS · app 2021552026-11-21
Regulatory context
FDA_EXCLUSIVITYELIQUIS SPRINKLE · PED2028-10-17
FDA_EXCLUSIVITYELIQUIS · PED2028-10-17
FDA_EXCLUSIVITYELIQUIS · NS2028-04-17
FDA_EXCLUSIVITYELIQUIS SPRINKLE · NP2028-04-17
FDA_APPROVALELIQUIS · 2025-04-17
FDA_APPROVALELIQUIS SPRINKLE · 2025-04-17
FDA_APPROVALAPIXABAN · 2024-12-17
FDA_APPROVALAPIXABAN · 2024-02-16
FDA_APPROVALAPIXABAN · 2023-02-27
FDA_APPROVALAPIXABAN · 2021-07-26
FDA_APPROVALAPIXABAN · 2020-09-11
FDA_APPROVALAPIXABAN · 2020-07-28
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.